Condition
Gynaecological Cancers
Total Trials
3
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07101081RecruitingPrimary
GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort
NCT07622953RecruitingPrimary
Vaginal Fluid Derived Biomarkers in the Early Detection and Evolution of Gynaecological Cancers
NCT04065269Phase 2Active Not RecruitingPrimary
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
Showing all 3 trials